Literature DB >> 24677397

New anti-complement drugs: not so far away.

Joshua M Thurman1.   

Abstract

In this issue of Blood, Risitano et al demonstrate that small-molecule inhibitors of C3 cleavage prevent complement activation on erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH); the authors demonstrate that these agents reach therapeutic concentrations after subcutaneous injection in nonhuman primates.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24677397      PMCID： PMC3968382          DOI： 10.1182/blood-2014-02-555805

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  The membrane attack complex.

Authors:  H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

2.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

Authors:  Richard J Kelly; Anita Hill; Louise M Arnold; Gemma L Brooksbank; Stephen J Richards; Matthew Cullen; Lindsay D Mitchell; Dena R Cohen; Walter M Gregory; Peter Hillmen
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

3.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Russell P Rother; Scott A Rollins; Christopher F Mojcik; Robert A Brodsky; Leonard Bell
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

4.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

5.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

6.  Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307
  6 in total
  5 in total

1.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

2.  The clinical implications of the unique glomerular complement deposition pattern in transplant glomerulopathy.

Authors:  Priya S Verghese; Robin C Reed; Bu Lihong; Arthur J Matas; Youngki Kim
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

3.  Identification of peptidic inhibitors of the alternative complement pathway based on Staphylococcus aureus SCIN proteins.

Authors:  Brady J Summers; Brandon L Garcia; Jordan L Woehl; Kasra X Ramyar; Xiaolan Yao; Brian V Geisbrecht
Journal:  Mol Immunol       Date:  2015-06-04       Impact factor: 4.407

4.  Donor Urinary C5a Levels Independently Correlate With Posttransplant Delayed Graft Function.

Authors:  Bernd Schröppel; Peter S Heeger; Heather Thiessen-Philbrook; Isaac E Hall; Mona D Doshi; Francis L Weng; Peter P Reese; Chirag R Parikh
Journal:  Transplantation       Date:  2019-01       Impact factor: 4.939

Review 5.  Novel Evasion Mechanisms of the Classical Complement Pathway.

Authors:  Brandon L Garcia; Seline A Zwarthoff; Suzan H M Rooijakkers; Brian V Geisbrecht
Journal:  J Immunol       Date:  2016-09-15       Impact factor: 5.422
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.